EKITA-DESCARTES Joint Symposium
SUNDAY 24 SEPTEMBER 2017 | 09:00-12.50
CHAIRS: Fritz Diekmann, Berlin, Germany
Ondrej Viklicky, Prague, Czech Republic
09:00-10:40 SESSION 1
09:00 Basics of the HLA system
Caner Süsal, Heidelberg, Germany
09:20 External validity and variability of solid phase results
Markus Wahrmann, Vienna, Austria
09:40 HLA single epitope matching become real?
Frans Claas, Leiden, The Netherlands
10:00 Preformed HLA DSAs and outcomes
Christophe Legendre, Paris, France
10:20 De novo HLA-DSAs and hard outcomes. How to determine risk (class, number, complement activation?)
Johan W. De Fijter, Leiden, The Netherlands
10:40 - 11:00 Break
11:00-12:50 SESSION 2
11:00 Alloimmunity trough non-HLA, the human knock out experiment
Rainer Oberbauer, Vienna, Austria
11:20 Complement blockade and outcomes – novel approaches beyond eculizumab
Georg Böhmig, Vienna, Austria
11:40 Treatment of ABMR features in management biopsies
Ondrej Viklicky, Praha, Czech Repuplic
12:00 Underlying mechanisms of spontaneous operational tolerance
Annick Massart, Brussels, Belgium
OBJECTIVES | To provide an overview and offer specific solutions for the ‘complicated’/sensitized patient. Solutions range from individualization through omics technologies to bioinformatics approaches.
TARGET AUDIENCE | Transplant surgeons and physicians, nephrologist, immunologists at all stages of training and expertise.
EKITA is the kidney section of ESOT and deals with all aspects of renal transplantation. As a European platform, EKITA supports research, education and clinical work in this area. Furthermore, EKITA is highly ambitious in preparing policies and creating transnational interactions to advance renal allografting in all European member states.
GOALS |The main goal of EKITA is to improve quality of life of people with ESRD by advancing all aspects of kidney transplantation.
AIM |The ultimate aim of EKITA is the optimization of renal transplantation trough activities in research, education, clinical collaboration and health policy.